Efficacy of erythroid‐stimulating agent and luspatercept in VEXAS syndrome: A multicenter retrospective study by the FRENVEX group
Saved in:
Main Authors: | Maël Heiblig, Vincent Jachiet, Jérôme Hadjadj, Lin Pierre Zhao, Thibault Comont, Hervé Lobbes, Valentin Lacombe, Anne Blandine Boutin, Joris Galland, Benjamin Terrier, Sophie Georgin‐Lavialle, Pierre Fenaux, Arsène Mekinian, the FRENVEX Group |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-06-01
|
Series: | HemaSphere |
Online Access: | https://doi.org/10.1002/hem3.70156 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
VEXAS Syndrome and Alzheimer’s Disease—Are There Connections?
by: Aleksandra Sowa, et al.
Published: (2025-05-01) -
Luspatercept versus mitapivat for non‐transfusion‐dependent β‐thalassemia: Dare to compare?
by: Khaled M. Musallam, et al.
Published: (2025-07-01) -
Is immunotherapy safe and effective in patients with VEXAS syndrome?
by: Chiara Marvisi, et al.
Published: (2025-07-01) -
Digital Track Map for the VEXA expert system
by: Adam Hlubuček
Published: (2022-05-01) -
Reorganisation of chromatin during erythroid differentiation
by: A. A. Khabarova, et al.
Published: (2019-02-01)